Identification of Potential Key Genes and Pathways in Enzalutamide-Resistant Prostate Cancer Cell Lines: A Bioinformatics Analysis with Data from the Gene Expression Omnibus (GEO) Database

Enzalutamide (ENZ) has been approved for the treatment of advanced prostate cancer (PCa), but some patients develop ENZ resistance initially or after long-term administration. Although a few key genes have been discovered by previous efforts, the complete mechanisms of ENZ resistance remain unsolved...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Long, Dou, Xiaojie, Ma, Xiaodong, Qu, Wei, Tang, Xiaoshuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382728/
https://www.ncbi.nlm.nih.gov/pubmed/32724813
http://dx.doi.org/10.1155/2020/8341097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382728/
https://www.ncbi.nlm.nih.gov/pubmed/32724813
http://dx.doi.org/10.1155/2020/8341097

Ejemplares similares